Bibliografía del artículo
1. Yew WW, Leung CC. Update in tuberculosis 2005. Am J Respir Crit Care Med 173:491-8, 2006.
2. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 173:927-31, 2006.
3. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting noncompletion of treatment for latent tuberculosis infection: a prospective survey. Am J Respir Crit Care Med 174:717-21, 2006.
4. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 175:75-9, 2007.
5. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med 176:930-5, 2007.
6. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for TB control. Am J Respir Crit Care Med 175:87-93, 2007.
7. De Vries G, Van Hest NA, Richardus JH. Impact of mobile radiographic screening on tuberculosis among drug users and homeless persons. Am J Respir Crit Care Med 176:201-7, 2007.
8. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 167:335-42, 2007.
9. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 167:1297-304, 2007.
10. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-80, 2006.
11. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45:1290-5, 2007.
12. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13:380-7, 2007.
13. Cooke GS, Campbell SJ, Sillah J, et al. Polymorphism within the interferon / receptor complex is associated with pulmonary tuberculosis. Am J Respir Crit Care Med 174: 339-43, 2006.
14. Fernando SL, Saunders BM, Sluyter R, et al. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175:360-6, 2007.
15. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 173: 803-10, 2006.
16. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumour necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195:1643-50, 2007.
17. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176:208-13, 2007.
18. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-gamma and TNF-independent vitamin D-inducible human suppression on mycobacteria: the role of cathelicidin LL-37. J Immunol 178:7190-8, 2007.
19. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 174:349-55, 2006.
20. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T cell responses following point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174:831-9, 2006.
21. Aiken AM, Hill PC, Fox A, et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6:66, 2006.
22. Ferrara G, Losi G, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367:1328-34, 2006.
23. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 28:24-30, 2006.
24. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175:282-7, 2007.
25. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Care Med 175:618-27, 2007.
26. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 175:514-20, 2007.
27. Luetkemeyer AF, Charlebois ED, Florres LL, et al. Comparison of an IFN- release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 175:737-42, 2007.
28. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis 44:69-73, 2007.
29. Kang YA, Lee HW, Hwang SS, et al. Usefulness of whole-blood interferon- assay and interferon- enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest 132:959-65, 2007.
30. Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 45:322-8, 2007.
31. Jafari C, Ernst M, Kalsdorf B, et al. Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am J Respir Crit Care Med 174:1048-54, 2006.
32. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine / isoniazid or daily rifampin / pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 173:922-6, 2006.
33. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 173:350-6, 2006.
34. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 174:94-101, 2006.
35. Burman WJ, Goldberg S, Johnson JL, et al. Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174:331-8, 2006.
36. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 175:1199-206, 2007.
37. Chang KC, Leung CC, Yew WW, Tam CM. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur Respir J 29:347-51, 2007.
38. Szklo A, Mello FC, Guerra RL, et al. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. Int J Tuberc Lung Dis 11:775-80, 2007.
39. Torun T, Tahaoglu K, Ozmen, et al. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 11:979-85, 2007.
40. Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 62:416-21, 2007.